Corona Viral Diseases – Cannabis Research

Corona Viral Diseases Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 97 studies associated with Corona Viral Diseases.

Here is a small sampling of Corona Viral Diseases studies by title:

Components of the Corona Viral Diseases Research Dashboard

  • Dosing information available for Corona Viral Diseases
  • Chemotype guidance for treating Corona Viral Diseases with cannabis
  • Synopsis of cannabis research for Corona Viral Diseases
  • Individual study details for Corona Viral Diseases

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Corona Viral Diseases

Description of Corona Viral Diseases

Coronaviruses are a family of hundreds of viruses that typically cause symptoms not unlike the common cold or flu. Until very recently and unlike the cold or flu corona viral infections affected only a relatively small numbers of people. All of that changed in the year 2002 with the emergence of first epidemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in southern China. By the time this epidemic was done the CDC reports ~8,000 patients had been infected in total with a ~10% mortality rate (no new cases since 2004). Humanities next brush with a member of the corona viral family came ten years later. This time originating in Saudi Arabia (2012) causing Middle East Respiratory Syndrome (MERS-CoV) with approximately 2,500 confirmed cases and a fatal rate of ~35% (MERS-CoV is still active). Fast forwarding to the next outbreak brings us to 2019 when news of a novel and mysterious respiratory illness reaches us from Wuhan, China. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that caused coronavirus disease 2019 (COVID-19). To the surprise and shock the global population this outbreak grew rapidly from an epidemic to a global pandemic. By December, 2020 the global count of corona virus cases was estimated to have surpassed 67 million people with an estimated 1.5 million fatalities (~2.2%). Corona viruses can be transmitted by zoonotic means that is they can be transmitted between animals and humans. The vectors for transmission are posited to be bats (considered primary viral reservoirs), camel (or dromedary), with other animals (e.g. masked palm civets ) acting as possible intermediaries. Patients who contract COVID-19 do not all get sick in the same way or with the same intensity of symptoms, which range from mild, moderate, or severe to fatal, depending on the resilience or constitution of the affected person. The CDC suggest that—based on the, better-understood member of the corona viral family, i.e., the 2012 appearance of the Middle East Respiratory Syndrome-Related Coronavirus, MERS-CoV—symptoms are likely to appear between 2 and 14 days after exposure (typically via airborne droplets). This estimate was fine-tuned by the most recent study from Johns Hopkins Bloomberg School of Public Health (2020) which discovered that the median incubation period for COVID-19 of was approximately 5 days.

Disease Classification

Condition: COVID-19
Disease Family:
Organ System: Respiratory System
ICD-10 Chapter: Certain Infectious and Parasitical Diseases
ICD-10 Code: U07.1

Corona Viral Diseases Symptoms:

Symptoms, can range from mild, moderate, or severe to fatal, depending on the resilience or constitution of the affected person. According to the CDC, the most common symptoms of COVID-19 are fever, dry cough, and shortness of breath. The World Health Organization (WHO) lists as most common symptoms (in descending order): fever, weakness (tiredness, fatigue), dry cough. The WHO also lists less commonly reported symptoms such as shortness of breath, aches and pains (i.e., bone, joint, muscle pains, headaches), sore throat, with a minority of patients reporting nasal congestion, nausea, and diarrhea.

Also known as:

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronoa Virus, SARS, MERS

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.